As investors we are bold, enthusiastic and take imaginative risks – we are not interested in following the crowd. We push the boundaries, drive innovation and foster our collaborative networks within industry, academia and public sector partners, specifically within the science and technology ecosystem. We take a long-term view to company development, making flexible full-spectrum investments from £50K to £160M. Our vision is to create a cluster of global innovation and excellence ‘Science Park + Investment + Industry’.
TusPark UK is a science and technology service with a venture capital and private equity group fund investment arm. TusPark UK has invested £230M+ in Cambridge since 2018 and its investment portfolio spans theareas of life sciences and healthcare, digital technologies (eg: big data, artificial intelligence and internet of things), new materials, and environmental & new energy, with the unique model of ‘Incubation + Investment + M&As’. We follow the science to invest in companies based on disruptive and revolutionary technologies that can impact and improve people’s lives.
From the discovery of penicillin in 1928 to the development of vaccines to tackle COVID-19, the UK is a global life sciences leader and innovator. TusPark UK values the UK’s scientific excellence and actively seeks breakthrough innovation that can deliver better patient outcomes and improve people’s quality of life. Our investment covers but is not limited to companies that develop innovative drugs, advanced cell and gene therapies, novel diagnostic and drug discovery platforms, CRO and CDMO as well as medical device and digital health companies.
Built on its engineering and technological ingenuity, the UK’s digital tech sector has been transforming the world, from artificial intelligence (AI) pioneers like DeepMind to the world-leading semiconductor designer ARM. TusPark UK is passionate about cutting-edge digital technologies in the UK, and through investment we constantly support ambitious companies that develop disruptive technologies such as AI and machine learning, quantum computing, cloud computing, semiconductor and financial technology as it reshapes every aspect of our lives.
Sustainability is one of the most pressing issues in a fast-changing energy landscape and a climate emergency. TusPark UK is highly engaged with and invests in companies within the UK sector of renewable energy and clean technologies including wind/solar power, energy storage, biomass and new material.
We bring value to our cross-border investees through a series of steps starting with an assessment of the opportunity before defining market entry strategy and supporting the creation of a local office, joint venture or M&A opportunity. Once in place we leverage the TUS network to support and develop the business locally with the aim of achieving organic growth, IPO or acquisition.
Discover more about some of our exciting and innovative investees, who are undertaking ground-breaking research and development across the life science, medtech and AI technology sectors.
With facilities in Cambridge and Newcastle, we enable UK-based companies to connect, collaborate and build relationships with like-minded investors and innovators in China. Explore our facilities below:
In a unique partnership with Trinity College, University of Cambridge and Cambridge Science park we have invested £200m across five buildings, including the Park’s first Bio-Innovation Centre. This investment puts us at the heart of the thriving technology and innovation sector in this world-leading city.
Home to Barclays Eagle Labs, our Newcastle space provides both co-working spaces and support for start-up including free networking events, seminars and access to legal, accounting and intellectual property support teams to facilitate growth.
Mogrify Limited (Mogrify®), a biopharmaceutical company located in Bio-Innovation Centre, announced today an additional $10 million USD closing of its Series A financing, bringing the total raised to $46 million USD in this round. The funding will support further advancement of Mogrify’s pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.Read More
We are delighted to be partnering with KPMG and Growth Works to jointly organise a workshop on fund raising, inviting Salvatore Di Maggio, Senior Manager of Growth Business at KPMG to discuss how to Find Your Way to Funding and Getting Investors Ready.Read More